GLYCOMICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Glycomics Market Size and Trends

The glycomics market is estimated to be valued at USD 1.99 Bn in 2024 and is expected to reach USD 4.82 Bn by 2031, growing at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2031.

To learn more about this report, request sample copy

The market is witnessing high growth due to increasing research activities in the field of glycomics. Glycomics helps in developing novel drug targets and precision medicine approaches for various diseases such as cancer and diabetes. Various initiatives by governments and private organizations are providing funding for glycomics research which is further supporting the market growth. Rising demand for glycan-based tests and growing application of glycomics in developing vaccines and biomarkers are some of the key factors driving the glycomics market growth.

Growing biopharmaceutical industry and rising research & development investments

The major driver behind the growth of the glycomics market is the rising need for glycomics technologies in drug discovery and development processes by biopharmaceutical companies. Glycans and glycoproteins play vital roles in various biological processes and disease mechanisms. Understanding protein glycosylation is important for developing antibodies, vaccines, and other therapeutic proteins. Over the past few years, there has been significant investments made by leading biopharmaceutical players in setting up glycan analysis facilities and collaborating with glycomics companies. They are using glycomic techniques to aid preclinical and clinical research in areas such as oncology, inflammation, and neurology. The drug development success rate has remained low for years, driving biopharma firms to bank on strategic innovations that can aid target identification and validation. Exploring glycobiology is seen as a promising approach, and this is reflected in the trend of rising R&D allocation towards applying glycomic tools and services.

Another major factor augmenting the glycomics market growth is the increasing demand for personalized healthcare and precision medicine-driven diagnostic solutions. Analysis of protein glycosylation patterns is garnering significance in disease biomarker discovery for various conditions including cancers. Glycans can serve as biomarkers indicative of specific disease subtypes or stages and patient response to therapies. Glycomic profiling is being extensively researched for clinical applications such as early disease detection, real-time health monitoring, predictive/prognostic testing, and treatment selection. Some key areas where glycans hold diagnostic potential include oncology, infectious diseases, autoimmune disorders, and metabolic diseases. This aligns well with the burgeoning trends of stratified medicine, companion diagnostics, and self-monitoring diagnostics. Glycoprofiling is anticipated to evolve into a vital tool supporting the shift towards customized and selective treatment approaches.